Gastrin Releasing Peptide (GRP) Antibody

Product specifications

Primary Antibodies

Target: Gastrin Releasing Peptide (GRP)
Immunogen: abx651230 - OVA-conjugated Gastrin Releasing Peptide (GRP)

Rabbit

Rat

WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.

Polyclonal

Unconjugated

Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.

100 µl

200 µl

1 ml

Liquid

WB, IHC, IF/ICC

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Shipped within 5-7 working days.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

P24393

BN,GRP-10,proGRP,preproGRP

Antibody anti-GRP

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Descripción

GRP is a neuropeptide that acts as the mammalian equivalent of bombesin, a peptide involved in stimulating the release of gastrin and other gastrointestinal hormones GRP is primarily secreted by nerve endings in the gastrointestinal tract and pancreas, where it regulates gastric acid secretion, gastrointestinal motility, and nutrient absorption It exerts its effects by binding to the gastrin-releasing peptide receptor (GRPR), a G-protein-coupled receptor GRP plays an important role in cell proliferation, wound healing, and neural signaling in the central nervous system Dysregulated GRP expression is associated with the pathogenesis of cancers, particularly small cell lung cancer (SCLC) and prostate cancer, where it promotes tumor cell growth and metastasis GRP and its receptor are also implicated in inflammatory processes and neurological conditions, making them potential targets for cancer therapy and gastrointestinal disorders

Related Products

Rat Gastrin Releasing Peptide (OVA)

Gastrin Releasing Peptide Protein (OVA) is a Rat protein conjugated to OVA.

Ver Producto